The HPLC method for the simultaneous determination of urinary neopterin, pseudouridine, and creatinine allows a rapid evaluation of the activation state of cell-mediated immunity, and the stimulation of whole-body rRNA + tRNA turnover, associated with malignant growth ..Urinary neopterin and pseudouridine concentrations in healthy subjects amounted to: 106.6 ± 34.6 μιηοΐ/mol creatinine, and 19.6 ± 5.2 mmol/mol creatinine (x ± SD), respectively. The increase of neopterin excretion in patients with haematological neoplasms ranged from 146% in Hodgkitfs disease to 534% in non-Hodgkin's lymphoma, whereas the increase in cancer cases ranged from 95% in adenocarcinoma of the gaster to 741% in hepatocellular carcinoma. The changes in pseudouridine excretion were much less pronounced: 63% in non-ffodgkin's lymphoma and 120% in carcinoma of the urinary bladder. The correlation coefficient between neopterin and pseudouridine was relatively low (r = 0.43), although statistically significant (P < 0.01). In the case of several neoplasms e.g. Hodgkin's disease, polycythaemia vera, and adenocarcinoma of the gaster, neopterin was significantly elevated, whereas pseudouridine remained at a normal concentration. There was a positive relationship between the stage of the disease (primary focus, regional metastases, dissemination) and urinary concentration of pseudouridine in patients with adenocarcinoma of the large intestine. In the same patients the increase of neopterin excretion was noticed both in early and advanced stages, with the highest values in disseminated disease.
Introduction
. , m ι i_ ,^ ~™ -Λ activated T-lymphocytes (1) . Thus, neopterin deterNeopterin and pseudouridine detected in biological mined in blood serum (2) and urine (3) is considered fluids are used as biochemical markers of malignancy, as a good marker of T-cell activation. A significant but the source and mechanism of their elevation are diurnal rhythm of neopterin in urine has been detected different. Determination of neopterin in blood plasma with a peak at 06.30 h (4). Hausen et al. (5) has and urine provides information about the activation reviewed malignant diseases associated with increased state of cell-mediated immunity in vivo. Neopterin is urinary and/or serum neopterin concentrations: haesynthesized from guanosine triphosphate by macro-matological neoplasms, gynaecological tumours, tumphages by the action of GTP cyclohydrolase, an en-ours of the genitourinary tract, lung cancer, gastrozyme induced by interferon gamma and derived from intestinal and pancratic carcinoma, melanomas, _ breast tumours, head and neck cancers.
* Nado'naf ^ Wttod by a gnmt from the Miniitry of The source of pseudouridine excreted in urine is ** Submitted March 30/August 31, 1992 to "Pteridines" which whole-body catabolism of tRNA and rRNA (6) . Pseudiscontinued with vol. 3, no. 3, 1992.
douridine is not re-utilized in nucleotide synthesis by the salvage pathway, appears in blood plasma, and is quantitatively excreted in urine (7) . Pseudouridine is generally excreted in concentrations of 10 to 100 times those of other nucleosides, both in healthy subjects and cancer patients (8, 9). There is a considerable number of publications concerning changes in urinary pseudouridine excretion evoked by malignant growth (9-15).
The present work was carried out to compare urinary neopterin and pseudouridine excretion in patients with haematological proliferative diseases and cancer. We offer a simple, sensitive and rapid HPLC method for the simultaneous determination of neopterin, pseudouridine and creatinine in the same urine sampie. 
Materials and Methods

Patients
Urine collection and preparation
The first morning urine of healthy individuals and patients with The mobile phase was 0.01 mol/1 potassium dihydrogen phosphate (pH 5.9) containing methanol, volume fraction 0.01, at a flow rate of 1 ml χ min"" 
Statistical analysis
Results were statistically evaluated by ANOVA and Tukey range test (the significance of differences between the means of each group and subgroup of patients), and Studenfs t-test (the significance of differences between control group and each group of tumour patients). Correlation coefficients were calculated by the method of least squares. The probability of differences between averages at the level Ρ < 0.05 was taken as significant, and at the level Ρ ^ 0.01 as highly significant.
Results and Discussion
The HPLC method for the simultaneous determination of urinary neopterin, pseudouridine and creatinine ( fig. 1 ) allows the rapid evaluation of the activation state of cell-mediated immunity and the rate of whole-body rRNA + tRNA turnover, associated with malignant growth. The values of urinary neopterin and pseudouridine concentrations in healthy subjects (106.6 ± 34.6 μπιοΐ/mol creatinine, and 19.5 ± 7.6 mmol/mol creatinine, respectively) are comparable to those described in earlier reports (4, 6).
Among haematological proliferative diseases, the highest increases (P < 0.01) of both analyses were observed in non^-Hodgkin's lymphoma (neopterin: 675.7 μιηοΐ/mol creatinine; pseudouridine: 31.8 mmol/ mql creatinine), chronic lymphocytic leukaemia (neopterin: 438.4 μιηοΐ/mol creatinine, pseudouridine: 29.5 mmol/mol creatinine), myelofibrosis, and multiple myeloma (fig. 2 ).
The increase of urinary neopterin excretion was evident (P < 0.01) in all examined cases of cancer ( fig.  2) with the highest values in hepatocellular carcinoma (897.0 μπιοΐ/mol creatinine), adenocarcinoma of the pancreas (632.7 nml/mmol creatinine), adenocarcinoma of the rectum (609.1 μιηοΐ/mol creatinine), and adenocarcinoma of the colon (566.8 μιηοΐ/mol creatinine). The highest concentrations of urinary pseudouridine were observed in carcinoma of the urinary bladder (42.8 mmol/mol creatinine), and hepatocellular carcinoma (37.5 mmol/mol creatinine).
Generally, the changes of urinary neopterin and pseudouridine excretion showed a similar trend, but not in all examined patients. This reflected in a relatively low, although statistically significant, correlation coefficient (r = 0.43, P < 0.01) between urinary neopterin and pseudouridine excretion. In several neo- plasms, e. g. Hodgkin's disease, polycythaemia vera, and adenocarcinoma of the gaster, neopterin was significantly elevated, whereas pseudouridine remained at a normal concentration. This confirms our findings of a poor response of blood plasma pseudouridine in the mentioned diseases (unpublished data). It should also be noted that elevations in urinary neopterin are much more pronounced than those of pseudouridine, both in haematological neoplasms and examined canĉ ers ( fig. 2) . The increase (expressed as % increase) of neopterin excretion in haematological proliferative diseases ranged from 146% in Hodgkin's disease to 534% in non-Hodgkin's lymphoma, whereas the highest increase of pseudouridine excretion in non-Hodgkin's lymphoma was 62%. Similarly, in cancer patients, the increase of neopterin excretion ranged from 95% in adenocarcinoma of the gaster to 741% in hepatocellular carcinoma, but the maximal increase of pseudouricline excretion of 120% was observed in carcinoma of the urinary bladder. This is also illustrated by figure 3 , where urinary excretion of neopterin and pseudouridine is presented in relation to the stage of adenocarcinoma of the large intestine. If the particular stages described as primary focus, regional metastases, and dissemination are assigned hypothetical values of 1, 2 and 4, respectively, the relationship between the stage and urinary pseudouridine excretion is statistically significant (r = 0.60, P < 0.01). It reflects the progressive increase of rRNA + tRNA turnover, associated with tumour burden. There was no such relationship between the stage of the disease and urinary neopterin, which was elevated both in early and advanced stages of malignant growth ( fig. 3 ). It seems important that both markers provide to some extent independent information about malignant growth (pseudouridine) and immune activation (neopterin) in the same patient. The lack of correlation between the changes observed in pseudouridine and neopterin in subgroups of patients could mean that not only malignant growth but also other influences e. g. degree of cell differentiation, are important in the induction of immune activation in patients.
In conclusion, urinary neopterin is a more sensitive biochemical marker of malignancy than pseudouridine. Simultaneous determination of neopterin, pseudouridine, and creatinine by HPLC is a simple, rapid, precise, and relatively inexpensive method, which can be useful in many medical laboratories.
